Company: INTS
Filing Date: 2025-05-13
Form Type: 8-K
Source: 0001567264-25-000040
Chunk: 0

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-05-13
Form: 8-K
Item: Item 2.02
Chunk 0
---
Item 2.02 Results of Operations and Financial Condition.

On May 13, 2025, Intensity Therapeutics, Inc. (the “ Company”) released its financial results for the three months ended March 31, 2025. A copy of the Company’s press release is attached as Exhibit 99.1 to this Form 8-K and incorporated herein by reference.

The information in this report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended (the “ Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

  Exhibit No.      Description                                                   
         99.1      Press Release issued Ma y 13, 2025.                           
 ─────────────────────────────────────────────────────────────────────────────────
          104      Cover Page Interactive Data File (formatted in Inline XBRL).  

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

Comments in this Current Report on Form 8-K and in the exhibit attached hereto contain certain forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act, which are based on management’s good faith expectations and beliefs concerning future developments. Actual results may differ materially from these expectations as a result of many factors. These factors include, but are not limited to, the risks and uncertainties described in the “ Risk Factors” and “ Cautionary Note Regarding Forward Looking Statements” sections of the Company’s Annual Report on Form 10-K, filed on March 13, 2025, and the Company's Quarterly Report on Form 10-Q, filed on May 13, 2025. The Company does not undertake any obligation to update such forward-looking statements. All market and industry data are based on Company estimates.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: May 13, 2025

  Intensity Therapeutics, Inc.                                                        
  By:                               /s/ Lewis H. Bender                               
                                    Name:                    Lewis H. Bender          
                                    Title:                   Chief